Aspire Biopharma (ASBP)
Market Price (3/30/2026): $0.89 | Market Cap: $1.1 MilSector: Health Care | Industry: Biotechnology
Aspire Biopharma (ASBP)
Market Price (3/30/2026): $0.89Market Cap: $1.1 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -121%, 3Y Excs Rtn is -162% | Penny stockMkt Price is 0.9 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1032838% | ||
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 593% | ||
| Expensive valuation multiplesP/SPrice/Sales ratio is 580x | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 728040% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -181148%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -181148% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2823% | ||
| High stock price volatilityVol 12M is 4170% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 40% | ||
| Key risksASBP key risks include [1] significant financial distress raising substantial doubt about its ability to continue as a going concern and [2] a potential delisting from Nasdaq for non-compliance. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -121%, 3Y Excs Rtn is -162% |
| Penny stockMkt Price is 0.9 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1032838% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 593% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 580x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 728040% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -181148%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -181148% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2823% |
| High stock price volatilityVol 12M is 4170% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 40% |
| Key risksASBP key risks include [1] significant financial distress raising substantial doubt about its ability to continue as a going concern and [2] a potential delisting from Nasdaq for non-compliance. |
Qualitative Assessment
AI Analysis | Feedback
Aspire Biopharma (ASBP) stock has lost about 80% since 11/30/2025 because of the following key factors:
1. Aspire Biopharma reported significant financial instability and expressed substantial doubt about its ability to continue as a going concern. The company filed its Q3 2025 report on November 14, 2025, revealing minimal net revenue of $1,941 and a net loss of $1,850,493 for the quarter. Furthermore, Aspire Biopharma disclosed a working capital deficit of $11,457,377.
2. Shareholders experienced substantial dilution and the company underwent a reverse stock split. On November 4, 2025, stockholders approved a reverse stock split ranging from 1-for-5 to 1-for-40. Additionally, shareholders authorized the issuance of over 19.99% of shares upon the exercise of convertible promissory notes. Overall, total shares outstanding grew by 332% in the past year, leading to significant dilution.
Show more
1. Aspire Biopharma reported significant financial instability and expressed substantial doubt about its ability to continue as a going concern. The company filed its Q3 2025 report on November 14, 2025, revealing minimal net revenue of $1,941 and a net loss of $1,850,493 for the quarter. Furthermore, Aspire Biopharma disclosed a working capital deficit of $11,457,377.
2. Shareholders experienced substantial dilution and the company underwent a reverse stock split. On November 4, 2025, stockholders approved a reverse stock split ranging from 1-for-5 to 1-for-40. Additionally, shareholders authorized the issuance of over 19.99% of shares upon the exercise of convertible promissory notes. Overall, total shares outstanding grew by 332% in the past year, leading to significant dilution.
Show more
Stock Movement Drivers
Fundamental Drivers
The -78.4% change in ASBP stock from 11/30/2025 to 3/29/2026 was primarily driven by a -78.4% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.23 | 0.91 | -78.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 2,697.0 | 582.6 | -78.4% |
| Shares Outstanding (Mil) | 1 | 1 | 0.0% |
| Cumulative Contribution | -78.4% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ASBP | -78.4% | |
| Market (SPY) | -5.3% | -0.0% |
| Sector (XLV) | -8.7% | -8.1% |
Fundamental Drivers
The -96.0% change in ASBP stock from 8/31/2025 to 3/29/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.01 | 0.91 | -96.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 582.6 | |
| Shares Outstanding (Mil) | 1 | 1 | -7.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ASBP | -96.0% | |
| Market (SPY) | 0.6% | -0.8% |
| Sector (XLV) | 5.2% | -7.4% |
Fundamental Drivers
The -98.5% change in ASBP stock from 2/28/2025 to 3/29/2026 was primarily driven by a -7.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 60.00 | 0.91 | -98.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | 582.6 | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | -7.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ASBP | -98.5% | |
| Market (SPY) | 9.8% | -0.0% |
| Sector (XLV) | -2.1% | -3.8% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ASBP | -99.8% | |
| Market (SPY) | 69.4% | -0.1% |
| Sector (XLV) | 18.4% | -3.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ASBP Return | - | 3% | 6% | 6% | -99% | -83% | -100% |
| Peers Return | 26% | 110% | 29% | 2% | 92% | -23% | 414% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| ASBP Win Rate | - | 78% | 75% | 67% | 50% | 0% | |
| Peers Win Rate | 52% | 48% | 44% | 44% | 62% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| ASBP Max Drawdown | - | -0% | -2% | -0% | -99% | -99% | |
| Peers Max Drawdown | -20% | -40% | -23% | -31% | -22% | -32% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AQST, INDV, COLL, PCRX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
null
nullIn The Past
null
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aspire Biopharma (ASBP)
N/A
AI Analysis | Feedback
nullAI Analysis | Feedback
```html- ASBI-003: A therapeutic candidate in development for the treatment of Pompe disease, a rare genetic disorder characterized by glycogen accumulation.
- ASBI-004: A therapeutic candidate in development for the treatment of Fabry disease, a rare genetic disorder caused by a deficiency of the alpha-galactosidase A enzyme.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Here is the management team for Aspire Biopharma (ASBP):Kraig Higginson, Interim Chief Executive Officer and Chairman of the Board
Mr. Higginson was appointed Interim Chief Executive Officer and Chairman of the Board in July 2025. He previously served as CEO of Aspire Biopharma for four years. Mr. Higginson has extensive experience in early-stage growth company management and public markets. He served as Chief Executive Officer of VIA Motors, Inc., a hybrid electric vehicle company, from November 2010 to January 2014. From October 2003 until November 2010, he was Chairman of the Board of Directors of Raser Technologies, Inc. He was also the founder, President, and Chief Executive Officer of American Telemedia Network, Inc. from 1984 to 1988.Ernest Scheidemann, Chief Financial Officer
Mr. Scheidemann serves as the Chief Financial Officer.Stephen Quesenberry, General Counsel & Corporate Secretary
Mr. Quesenberry serves as the General Counsel & Corporate Secretary for Aspire Biopharma Holdings, Inc.Howard Doss, Director and Chairman of the Audit Committee
Mr. Doss was appointed Director and Chairman of the Audit Committee in July 2025. He is a seasoned chief financial officer and accountant with vast experience. His previous roles include Chief Financial Officer for PowerUp (August 2023 - February 2025), Kernel Group Holdings, Inc., Aesther Healthcare Acquisition Corp. (2021-2023), and Trade Health, Inc. (SCNX). He also served as CFO and Director for Sansur Renewable Energy from 2010 to 2012 and Chief Financial & Accounting Officer at TRxADE HEALTH, Inc. from 2014 to 2022. Mr. Doss founded STARadio Corp. in 1985 and has served as its President since 2005. He is a member of the American Institute of CPA's.Phillip Balatsos, Director
Mr. Balatsos was appointed to the Board of Directors, effective February 6, 2026. He brings over 25 years of experience in financial markets, having held leadership positions at global financial institutions such as Barclays Capital, Credit Suisse, and XP Investments. He currently works at Oscar Gruss & Son and serves on the boards of Inspire Veterinary Partners, Inc. and Ciso Global, Inc. Mr. Balatsos also has entrepreneurial experience, having founded a hospitality business and advised restaurant groups on operational efficiency.AI Analysis | Feedback
The key risks for Aspire Biopharma (ASBP) are primarily centered around its financial health, the inherent challenges of drug development within the biotechnology sector, and the successful commercialization of its products.
- Significant Financial Challenges: Aspire Biopharma faces substantial financial difficulties, as indicated by a GF Score of 18, which suggests significant financial challenges. The company's current and quick ratios are both at 0.09, pointing to potential liquidity issues. Furthermore, a negative debt-to-equity ratio of -0.88 and an Altman Z-Score of 0 highlight its financial distress. The company has negative earnings per share and cash flow from operations, and a shocking return on assets of -1,110.97%. Aspire Biopharma is grappling with a surge in long-term debt against dwindling cash reserves, high operating costs, and low revenue streams. This has led to substantial shareholder dilution in the past year. The Altman-Z score of -41.84 specifically indicates a risk of bankruptcy.
- High Research and Development Costs and Regulatory Hurdles: As a biotechnology company, Aspire Biopharma operates in a sector characterized by high research and development (R&D) costs and stringent regulatory hurdles. The success of the company's drug candidates, such as its sublingual aspirin (OTASA) and other proposed sublingual medications for diabetes, weight management, and ED, is contingent on successful clinical trials that demonstrate efficacy and safety to regulatory authorities. Delays or failures in these trials, or in obtaining marketing approval from agencies like the FDA, could lead to increased costs or an inability to complete product development and commercialization. The company also highlights its limited operating history and the need to obtain additional funding for operations and to complete the development and commercialization of its drug candidates as a risk.
- Product Commercialization and Market Acceptance: The long-term viability of Aspire Biopharma depends heavily on the successful commercialization and broader market acceptance of its patented technologies and drug candidates. While the company is advancing its pipeline with a focus on sublingual delivery systems, the ability to achieve commercial success for these drug candidates, if approved, remains a key risk. The company plans to engage a commercialization partner, indicating a reliance on third parties for the execution of its marketing, distribution, and sales strategies, which introduces additional dependency.
AI Analysis | Feedback
nullAI Analysis | Feedback
Aspire Biopharma (ASBP) is an early-stage biopharmaceutical company focused on developing and marketing disruptive technology for novel sublingual (under the tongue) delivery mechanisms for a range of drugs, nutraceuticals, and supplements.
The addressable markets for Aspire Biopharma's main products and pipeline candidates are as follows:
- Instaprin (Sublingual Aspirin for Cardiology Emergencies and Pain Management): The global aspirin market was valued at approximately USD 2.1 billion in 2023 and is projected to reach around USD 3.2 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.8% from 2024 to 2032. The U.S. aspirin market was projected to be USD 793.58 million in 2024.
- Melatonin Sleep-Aid Products: The global melatonin supplement market was estimated at USD 3.31 billion in 2025 and is predicted to increase to approximately USD 13.32 billion by 2035, expanding at a CAGR of 14.94% from 2026 to 2035. North America held the largest share of the global melatonin supplement market in 2025.
- Testosterone Replacement Therapy Products: The global testosterone replacement therapy market size was valued at USD 1.9 billion in 2024 and is expected to grow at a CAGR of 4.2% from 2025 to 2034, reaching USD 2.9 billion. The U.S. testosterone replacement therapy market accounted for USD 736.1 million in 2024. North America generated 47.60% of the market size in 2025.
- Semaglutide Products: The global semaglutide market size was valued at USD 29.14 billion in 2024 and is anticipated to register a CAGR of 10.8% from 2025 to 2034. North America accounted for the largest share in 2024.
- Erectile Dysfunction (ED) Drugs: The global erectile dysfunction drugs market size was valued at around USD 2.9 billion in 2024 and is estimated to grow at a 9.2% CAGR from 2025 to 2034, reaching USD 7 billion. North America dominated the market in 2024. The U.S. erectile dysfunction drugs market is projected to reach USD 2.6 billion by 2034.
- Caffeine Products (Pre-Workout Supplements): The global pre-workout supplements market was valued at USD 19.90 billion in 2023 and is estimated to reach USD 29.77 billion by 2032, growing at a CAGR of 4.58%. North America dominates the global pre-workout supplements market.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Aspire Biopharma (ASBP) over the next 2-3 years:- Regulatory Approval and Commercial Launch of Instaprin: Aspire Biopharma's lead pharmaceutical product candidate, Instaprin (a sublingual high-dose aspirin), is being developed for the emergency treatment of suspected acute myocardial infarction. The company has a strategic roadmap targeting a New Drug Application (NDA) submission to the FDA in the second half of 2025. Successful approval and subsequent commercialization of Instaprin in the multi-billion-dollar cardiology emergency and pain management markets are expected to be a significant driver of revenue growth.
- Advancement and Commercialization of Broad Sublingual Pipeline: Beyond Instaprin, Aspire Biopharma is actively developing a pipeline of other sublingually administered formulations. This includes products such as a sublingual erectile dysfunction (ED) medication and a sublingual version of Semaglutide, with plans to complete formulation and initiate clinical studies for these in early 2026. The successful progression through clinical trials and eventual commercialization of these and other pipeline products (including melatonin, vitamins, testosterone, anti-nausea, anti-psychotic, and seizure medications) could significantly contribute to future revenue.
- Expanded Market Penetration and Sales Growth of BUZZ BOMB™ Sublingual Caffeine: Aspire Biopharma has a commercial presence in the nutraceutical and supplement market with its BUZZ BOMB™ sublingual caffeine product. Recent reports indicate the product has achieved "record social media growth and sales surge" and is expanding into new distribution channels, such as convenience stores. Continued expansion of its market reach and increased sales volume for BUZZ BOMB™ are anticipated to drive revenue growth in the near term.
AI Analysis | Feedback
Capital Allocation Decisions for Aspire Biopharma (ASBP)
Share Issuance
- In February 2026, Aspire Biopharma secured up to $21 million in convertible preferred stock financing from select investors, with an initial closing on February 6, 2026, raising $11.0 million. These funds are intended to repay existing debt, support operations and strategic initiatives, and help the company regain compliance with Nasdaq listing requirements.
- In January 2026, the company entered into a Securities Purchase Agreement to sell 8% OID Debentures for gross proceeds of $2.0 million. In connection with this financing, purchasers received 790,000 shares of ASBP's common stock as incentive shares.
- Aspire Biopharma issued a senior secured convertible debenture for $3.0 million in gross proceeds in February 2025, with proceeds designated for general working capital and operating expenses. This debenture is convertible in case of default or at the company's discretion.
Inbound Investments
- Aspire Biopharma secured up to $21 million through a private placement of convertible preferred stock in February 2026, with an initial $11.0 million received on February 6, 2026. The investment aims to strengthen the company's balance sheet, capital position, and shareholder equity to meet Nasdaq requirements.
- The company received $3.0 million in gross proceeds from a senior secured convertible debenture issued in February 2025, which was intended to support general working capital and operating expenses.
Capital Expenditures
- Specific dollar values for capital expenditures for Aspire Biopharma were not readily available in the provided information.
Trade Ideas
Select ideas related to ASBP.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 22.88 |
| Mkt Cap | 1.0 |
| Rev LTM | 726 |
| Op Inc LTM | 34 |
| FCF LTM | -4 |
| FCF 3Y Avg | 60 |
| CFO LTM | -4 |
| CFO 3Y Avg | 67 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.0% |
| Rev Chg 3Y Avg | 7.2% |
| Rev Chg Q | 11.3% |
| QoQ Delta Rev Chg LTM | 2.9% |
| Op Mgn LTM | 4.6% |
| Op Mgn 3Y Avg | 16.0% |
| QoQ Delta Op Mgn LTM | -0.8% |
| CFO/Rev LTM | -2.2% |
| CFO/Rev 3Y Avg | 7.4% |
| FCF/Rev LTM | -7.6% |
| FCF/Rev 3Y Avg | 4.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.0 |
| P/S | 2.9 |
| P/EBIT | 5.9 |
| P/E | 16.3 |
| P/CFO | -0.3 |
| Total Yield | 0.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.9% |
| D/E | 0.4 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -11.5% |
| 3M Rtn | -32.9% |
| 6M Rtn | -9.4% |
| 12M Rtn | 9.2% |
| 3Y Rtn | 33.1% |
| 1M Excs Rtn | -6.2% |
| 3M Excs Rtn | -24.5% |
| 6M Excs Rtn | -7.2% |
| 12M Excs Rtn | -3.2% |
| 3Y Excs Rtn | -26.9% |
Price Behavior
Price Behavior
| Market Price | $0.91 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -96.8% | |
| 50 Days | 200 Days | |
| DMA Price | $19.63 | $173.46 |
| DMA Trend | down | down |
| Distance from DMA | -95.3% | -99.5% |
| 3M | 1YR | |
| Volatility | 8,463.5% | 4,194.6% |
| Downside Capture | -7.02 | -1.70 |
| Upside Capture | -2345.95 | -535.46 |
| Correlation (SPY) | 0.1% | -0.2% |
ASBP Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.57 | -16.60 | -14.44 | -9.13 | -0.74 | -0.26 |
| Up Beta | 3.13 | -0.49 | -3.78 | -6.47 | 1.18 | 0.57 |
| Down Beta | 9.16 | 328.98 | 249.91 | 121.44 | 31.15 | 16.87 |
| Up Capture | 169% | -845% | -587% | -220% | -58% | -7% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 7 | 12 | 19 | 47 | 103 | 229 |
| Down Capture | 295% | -20132% | -14439% | -3729% | -859% | 16% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 14 | 29 | 41 | 76 | 145 | 250 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ASBP | |
|---|---|---|---|---|
| ASBP | -96.5% | 4,169.5% | 0.96 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | -4.0% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | -0.3% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -2.8% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -1.6% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 7.8% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 0.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ASBP | |
|---|---|---|---|---|
| ASBP | -69.0% | 2,631.4% | 0.57 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | -2.7% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 0.1% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | -2.2% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -0.7% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 4.2% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 0.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ASBP | |
|---|---|---|---|---|
| ASBP | -44.3% | 2,631.4% | 0.57 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | -2.7% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 0.1% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -2.2% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -0.7% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 4.2% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 0.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.